logo
Plus   Neg
Share
Email

FDA Approves Catalyst Pharma's Drug To Treat Rare Autoimmune Disorder

The U.S. Food and Drug Administration approved Firdapse or amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome or LEMS in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS. The FDA granted the approval of Firdapse to Catalyst Pharmaceuticals Inc. (CPRX).

In people with LEMS, the body's own immune system attacks the neuromuscular junction (the connection between nerves and muscles) and disrupts the ability of nerve cells to send signals to muscle cells. LEMS may be associated with other autoimmune diseases, but more commonly occurs in patients with cancer such as small cell lung cancer, where its onset precedes or coincides with the diagnosis of cancer. The prevalence of LEMS is estimated to be three per million individuals worldwide.

The most common side effects experienced by patients in the clinical trials were burning or prickling sensation (paresthesia), upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension and muscle spasms. Seizures have been observed in patients without a history of seizures. Patients should inform their health care provider immediately if they have signs of hypersensitivity reactions such as rash, hives, itching, fever, swelling or trouble breathing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook said it has launched an improved version of its automatic alternative text or AAT feature to improve photo descriptions for its users who are blind or visually impaired. AAT utilizes object recognition to generate descriptions of photos on demand so that blind or visually impaired, or BVI individuals, can more fully enjoy their News Feed. Morgan Stanley (MS) reported Wednesday a profit for the fourth-quarter that climbed 57 percent from last year, reflecting strong performance across all three business segments. Both earnings per share and quarterly revenue beat analysts' estimates. Billionaire and Alibaba co-founder Jack Ma made his first public appearance after nearly three months while delivering a speech to rural teachers in China in a live virtual meeting on Wednesday morning. He has been out of public view since late October, when he made a controversial speech at a Shanghai financial forum.
Follow RTT